Serevent
Product Images NDC 68258-8961

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Serevent (NDC 68258-8961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Salmeterol Xinafoate Chemical Structure (42aa9a5a C1f5 41ae Ba72 E9a46db63786 01)

Chemical structure of SEREVENT DISKUS active ingredient, depicted with hydroxyl, carboxyl, and aromatic groups. The structure shows multiple rings and side chains characteristic of the molecule.*

FDA Label Image

Figure 1. Serial 12-hour Fev1 From Two 12-week Clinical Trials In Patients With Asthma First Treatment Day (42aa9a5a C1f5 41ae Ba72 E9a46db63786 02)

A line graph comparing percent predicted forced expiratory volume in one second (FEV1) over 12 hours for three groups: SEREVENT DISKUS 50 mcg twice daily, Albuterol inhalation aerosol 180 mcg 4 times daily, and placebo. The graph shows FEV1 values on the vertical axis and time in hours on the horizontal axis.*

FDA Label Image

Last Treatment Day (week 12) (42aa9a5a C1f5 41ae Ba72 E9a46db63786 03)

A line graph comparing the effect of SEREVENT DISKUS 50 mcg twice daily, Albuterol inhalation aerosol 180 mcg 4 times daily, and placebo on FEV1 (% of predicted) over 12 hours. The graph shows FEV1 values on the vertical axis and time in hours on the horizontal axis, illustrating the drugs' bronchodilator impact over time.*

FDA Label Image

Figure 2. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (42aa9a5a C1f5 41ae Ba72 E9a46db63786 04)

This image contains three cumulative incidence graphs depicting asthma-related death over a duration of treatment in days. The graphs compare Salmeterol and placebo groups for all subjects, Caucasians, and African Americans, showing the number at risk at the start of each interval. The y-axis represents asthma-related death incidence, and the x-axis shows treatment duration up to 196 days.*

FDA Label Image

Figure 3. Mean Percent Change From Baseline In Postdose Fev1 Integrated Data From 2 Trials Of Patients With Chronic Bronchitis And Airflow Limitation (42aa9a5a C1f5 41ae Ba72 E9a46db63786 05)

A bar graph comparing the percent change in FEV1 for SEREVENT DISKUS 50 mcg twice daily versus placebo across Day 1, Week 12, Week 24, and Endpoint. Data points show higher percent changes for SEREVENT DISKUS compared to placebo at each time interval, with subject numbers provided below each category.*

FDA Label Image

Figure 4. Serial 12-hour Fev1 On The First Day And At Week 12 Of Treatment (42aa9a5a C1f5 41ae Ba72 E9a46db63786 06)

A line graph showing the change from baseline FEV1 (L/sec) over 12 hours after dosing on Day 1 and Week 12 for SEREVENT DISKUS 50 mcg twice daily versus placebo. The graph compares lung function improvement over time between treatment and placebo groups, with multiple lines representing different time points and groups.*

FDA Label Image

Pil Parts Figure (42aa9a5a C1f5 41ae Ba72 E9a46db63786 07)

Illustration of the SEREVENT DISKUS inhalation device showing labeled parts including the outer case, dose indicator, thumbgrip, lever, and mouthpiece. The central label identifies the product and dosage strength as 50 mcg dry powder inhaler.*

FDA Label Image

Pil Figure 1 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 08)

SEREVENT DISKUS 50 mcg inhalation powder device shown in close-up. The image focuses on part of the circular label displaying the brand name, strength, and active ingredient salmeterol xinafoate, along with the contoured gray plastic inhaler body. The label includes legible printed text and dosage information.*

FDA Label Image

Pil Figure 2 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 09)

An instructional illustration showing hands holding a SEREVENT DISKUS inhaler. The image demonstrates how to hold and prepare the inhaler for use, with an arrow indicating the direction to rotate the inhaler to activate a dose.*

FDA Label Image

Pil Figure 3 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 10)

An instructional image showing how to operate the SEREVENT DISKUS inhaler. The photo demonstrates a hand holding the Diskus while the thumb pushes a lever to prepare the dose, indicated by a white arrow pointing outward.*

FDA Label Image

Pil Figure 4 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 11)

Black and white instructional image showing a woman holding a SEREVENT DISKUS inhaler near her mouth, demonstrating its use for inhalation.*

FDA Label Image

Pil Figure 5 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 12)

An instructional illustration showing a woman using a SEREVENT DISKUS inhaler. She is placing the inhaler mouthpiece to her lips and appears to be inhaling the medication through the device.*

FDA Label Image

Pil Figure 6 (42aa9a5a C1f5 41ae Ba72 E9a46db63786 13)

An instructional black-and-white photo demonstrating hand positioning while preparing to use a SEREVENT DISKUS inhaler. One hand holds the inhaler, while the other rotates the white lever, indicated by a large white arrow pointing to the right, to load a dose.*

FDA Label Image

Ndc 68258-8961-06 (Ndc 68258 8961 06 Glaxosmithkline)

SEREVENT DISKUS 50 mcg inhalation powder label displaying 60 blisters (60 doses) per container. The label includes product NDC 68258-8961-06 and notes each blister contains 50 mcg of salmeterol base with lactose monohydrate. It also shows dispensing instructions, storage warnings, and the labeler Dispensing Solutions, Inc., Santa Ana, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.